Liquidia Co. (NASDAQ:LQDA) CFO Sells $45,722.88 in Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 3,136 shares of the business’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $45,722.88. Following the completion of the sale, the chief financial officer now owns 315,045 shares of the company’s stock, valued at approximately $4,593,356.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Monday, March 18th, Michael Kaseta sold 12,166 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total transaction of $192,466.12.

Liquidia Trading Up 2.1 %

LQDA opened at $13.86 on Thursday. Liquidia Co. has a one year low of $5.71 and a one year high of $16.99. The business’s fifty day moving average is $14.75 and its two-hundred day moving average is $10.95.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The business had revenue of $4.53 million during the quarter, compared to analysts’ expectations of $5.29 million. Analysts forecast that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LQDA. Fortitude Family Office LLC purchased a new position in Liquidia during the fourth quarter worth $26,000. Tower Research Capital LLC TRC boosted its stake in shares of Liquidia by 101.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock worth $55,000 after purchasing an additional 3,524 shares during the last quarter. UBS Group AG raised its position in shares of Liquidia by 134.0% in the second quarter. UBS Group AG now owns 7,948 shares of the company’s stock valued at $35,000 after buying an additional 4,552 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Liquidia during the second quarter valued at approximately $38,000. Finally, Tower Research Capital LLC TRC grew its stake in Liquidia by 610.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company’s stock worth $108,000 after acquiring an additional 7,731 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LQDA. LADENBURG THALM/SH SH increased their target price on shares of Liquidia from $15.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, December 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Liquidia in a research note on Wednesday, April 10th. HC Wainwright lifted their target price on Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, March 14th. Wedbush restated an “underperform” rating and set a $3.00 price target on shares of Liquidia in a research note on Thursday, December 21st. Finally, Bank of America raised their price target on Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, December 21st. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).